- Home
- ROIV vs CELH Comparison
ROIV vs CELH Comparison
Compare ROIV & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CELH |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 12.5B |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CELH |
|---|---|---|
| Price | $28.12 | $44.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | $27.56 | ★ $66.50 |
| AVG Volume (30 Days) | 4.8M | ★ 5.6M |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $29,053,000.00 | ★ $1,318,014,000.00 |
| Revenue This Year | N/A | $35.89 |
| Revenue Next Year | $385.85 | $11.06 |
| P/E Ratio | ★ N/A | $174.72 |
| Revenue Growth | N/A | ★ 101.65 |
| 52 Week Low | $8.73 | $27.15 |
| 52 Week High | $30.33 | $66.74 |
Technical Indicators
Market Signals| Indicator | ROIV | CELH |
|---|---|---|
| Relative Strength Index (RSI) | 53.51 | 41.84 |
| Support Level | $26.94 | $41.58 |
| Resistance Level | N/A | $47.24 |
| Average True Range (ATR) | 1.01 | 2.44 |
| MACD | -0.21 | -0.32 |
| Stochastic Oscillator | 32.70 | 15.64 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.